6533b833fe1ef96bd129ca88

RESEARCH PRODUCT

Combination of eribulin (E) and capecitabine (C) in elderly metastatic breast cancer (MBC): Update of a new option suitable in older elderly.

Antonio RussoDario CovaIgnazio CarrecaGiuseppe BronteAnna Paola CarrecaViviana Bazan

subject

OncologyCancer Researchmedicine.medical_specialtyChemotherapyMicrotubule dynamicsMesylatebusiness.industrymedicine.medical_treatmentPharmacologymedicine.diseaseMetastatic breast cancerCapecitabinechemistry.chemical_compoundOncologychemistryInternal medicinemedicinebacteriabusinessmedicine.drugEribulin

description

9540 Background: E mesylate, a nontaxane microtubule dynamics inhibitor is widely prescribed for MBC pts pretreated with at least 1-2 lines of chemotherapy, including anthracyclines and taxanes (A&...

https://doi.org/10.1200/jco.2015.33.15_suppl.9540